Johnson & Johnson (JNJ) stock prices updated...
 

Johnson & Johnson stock price, JNJ

Johnson & Johnson stock chart:



Johnson & Johnson close price: 125.48

Stock price forecast:

DOWN TO -4.34%
Target: 120.04

Total forecasts: 89
Reached: 51 (57.30%)

Total Win: 85.40 (74.86%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90915257.14%86.620.83%4,824.05-69.67-1.44%16.950.16%
303100.00%0.000.00%3,877.39-12.49-0.32%-12.49-0.32%
141500.00%0.000.00%1,906.9224.721.30%24.721.30%
7800.00%0.000.00%1,017.1413.301.31%13.301.31%

Showing 1-10 of 512 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-03-25125.48120.040000-00-00
2017-03-24125.9120.070000-00-00
2017-03-23126.26119.890000-00-00
2017-03-22127.25120.040000-00-00
2017-03-21128.07120.020000-00-00
2017-03-20128.06120.140000-00-00
2017-03-19128.06119.830000-00-00
2017-03-18128.06119.690000-00-00
2017-03-17128.46119.690000-00-00
2017-03-16128.96119.540000-00-00

Johnson & Johnson latest news:


  • 03/09/2017 14:06:12

    Stocks close fractionally higher as ECB stands pat on easing

    U.S. stocks finished slightly higher Thursday after European Central Bank President Mario Draghi left easing measures in place but downplayed deflation concerns. The Dow Jones Industrial Average advanced 2.46 points to finish at 20,858.19 led higher by shares of Johnson & Johnson Inc. . The S&P 500 index closed up 1.89 points, or just under 0.1%, at 2,364.87, as health-care and energy stocks gained. The Nasdaq Composite index finished up 1.25 points at 5,838.81.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 03/03/2017 15:01:27

    Johnson & Johnson wins trial in talc product liability lawsuits

    - Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.

  • 02/23/2017 10:55:54

    Stocks of manufacturers whose CEOs are meeting Trump mostly lower, led by US Steel

    The stocks of the manufacturing companies which were meeting with President Donald Trump Thursday were trading mostly lower. The drop comes amid reports that an infrastructure spending plan may be delayed until next year, and tax reform pushed back until at least the summer. United States Steel Corp. led the decliners, falling 6.7% in mid-morning trade. Caterpillar Inc. fell 2.4%, and Emerson Electric Co. fell 1.7%. Lockheed Martin Corp. and Corning Inc. were all down 0.7%. GE was down 0.5%, Whirlpool Corp. was down 0.4% and Dow Chemical Co. was down 0.3%. Goldman Sachs Group Inc. shares were trading down 0.7%. Goldman and Caterpillar combined were shaving about 30 points off the Dow Jones Industrial Average . Trump introduced Goldman's ex-COO Gary Cohn, now National Economic Council director, to the group as "Gary from Goldman." The only two stocks to gain were Johnson & Johnson and International Paper Co. , which were both up less than 1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/26/2017 14:24:56

    Johnson & Johnson refills drug cabinet with $30 billion Actelion deal

    ALLSCHWIL, Switzerland (Reuters) - U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

  • 01/26/2017 12:18:20

    Johnson & Johnson agrees $30bn deal for Actelion 

    Founder Jean-Paul Clozel to head up standalone spin-off research company

  • 01/26/2017 02:28:47

    Johnson & Johnson to buy Actelion for $30bn

    Swiss biotech group’s founder to head up standalone spin-off research company

  • 01/26/2017 01:52:18

    Johnson & Johnson to Acquire Actelion for $30 Billion

    The acquisition of the Swiss biotechnology company will improve Johnson & Johnson’s portfolio of drugs to treat rare diseases.

  • 01/26/2017 01:38:57

    Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit

    ZURICH (Reuters) - U.S. healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

  • 01/24/2017 10:22:00

    Johnson & Johnson Opens 2017 on a Cautious Note

    The healthcare conglomerate forecast lower revenue and earnings growth than investors had hoped.

  • 01/06/2017 00:01:42

    J&J, Actelion approach Swiss takeover board over deal structure: paper

    ZURICH (Reuters) - Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

  • 12/29/2016 09:00:34

    Exclusive: J&J discussing breaking up Actelion in an acquisition - sources

    (Reuters) - Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.

  • More trends:

    Johnson ControlsJCI | Jones EnergyJONE+30.87% | Jones Lang LaSalle IncorporatedJLL | Journal Media GroupJMG | Joy Global Inc.JOY | JP Energy Partners LPJPEP | JPMorgan China Region FundJFC | Jumei International Holding LimitedJMEI | Juniper NetworksJNPR | Jupai Holdings LimitedJP |